THEODORE B. SCHWARTZ, M.D., F.A.C.P.
▸Requests for reprints should be addressed to Theodore B. Schwartz, M.D., 1753 West Congress Pkwy., Chicago, Ill. 60612
SCHWARTZ T.; The Tolbutamide Controversy: A Personal Perspective. Ann Intern Med. 1971;75:303-306. doi: 10.7326/0003-4819-75-2-303
Download citation file:
Published: Ann Intern Med. 1971;75(2):303-306.
It is only with some difficulty that even the older clinician can recall the days before the advent of tolbutamide for the treatment of maturity-onset diabetes. This is because tolbutamide, other sulfonylureas, and the biguanides have entrenched themselves as highly satisfactory therapeutic agents. Until 13 years ago the treatment of the adult-onset, obese diabetic often evolved into a battle between a concerned physician, who sternly offered the alternatives of prodigious weight loss and daily insulin injections, and a reluctant patient whose mood ranged from anxiety and hostility through desperation and despair. Despite early cautionary voices, the oral hypoglycemic agents were
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Endocrine and Metabolism, Hospital Medicine.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only